Age 0 3 0 3 B-age
greater 4 11 4 11 O
than 12 16 12 16 O
or 17 19 17 19 O
equal 20 25 20 25 O
to 26 28 26 28 O
6 29 30 29 30 B-lower_bound
months 31 37 31 37 I-lower_bound

Availability 0 12 38 50 O
of 13 15 51 53 O
metreleptin 16 27 54 65 B-treatment
to 28 30 66 68 O
the 31 34 69 72 O
patient 35 42 73 80 O
either 43 49 81 87 O
as 50 52 88 90 O
an 53 55 91 93 O
approved 56 64 94 102 O
drug 65 69 103 107 O
, 69 70 107 108 O
or 71 73 109 111 O
through 74 81 112 119 O
local 82 87 120 125 O
compassionate 88 101 126 139 O
use 102 105 140 143 O
or 106 108 144 146 O
expanded 109 117 147 155 O
access 118 124 156 162 O
programs 125 133 163 171 O

Decrease 0 8 172 180 O
in 9 11 181 183 O
episodes 12 20 184 192 O
of 21 23 193 195 O
pancreatitis 24 36 196 208 B-chronic_disease

Decrease 0 8 209 217 O
in 9 11 218 220 O
insulin 12 19 221 228 B-clinical_variable
requirements 20 32 229 241 I-clinical_variable
greater 33 40 242 249 O
than 41 45 250 254 O
or 46 48 255 257 O
equal 49 54 258 263 O
to 55 57 264 266 O
40 58 60 267 269 B-lower_bound
% 60 61 269 270 I-lower_bound

Documented 0 10 271 281 O
metabolic 11 20 282 291 O
benefit 21 28 292 299 O
from 29 33 300 304 O
prior 34 39 305 310 B-treatment
or 40 42 311 313 I-treatment
current 43 50 314 321 I-treatment
metreleptin 51 62 322 333 I-treatment
treatment 63 72 334 343 I-treatment

HbA1c 0 5 344 349 B-clinical_variable
reduction 6 15 350 359 I-clinical_variable
greater 16 23 360 367 O
than 24 28 368 372 O
or 29 31 373 375 O
equal 32 37 376 381 O
to 38 40 382 384 O
1 41 42 385 386 B-lower_bound
% 42 43 386 387 I-lower_bound

Improvement 0 11 388 399 O
in 12 14 400 402 O
steatohepatitis 15 30 403 418 B-chronic_disease

Known 0 5 419 424 O
HIV 6 9 425 428 B-chronic_disease
infection 10 19 429 438 I-chronic_disease
or 20 22 439 441 O
HIV 23 26 442 445 O
- 26 27 445 446 O
associated 27 37 446 456 O
lipodystrophy 38 51 457 470 B-chronic_disease

Partial 0 7 471 478 B-chronic_disease
lipodystrophy 8 21 479 492 I-chronic_disease
( 22 23 493 494 O
either 23 29 494 500 O
genetic 30 37 501 508 O
or 38 40 509 511 O
acquired 41 49 512 520 O
) 49 50 520 521 O

Previously 0 10 522 532 O
or 11 13 533 535 O
currently 14 23 536 545 O
treated 24 31 546 553 O
with 32 36 554 558 O
metreleptin 37 48 559 570 B-treatment
under 49 54 571 576 O
NIH 55 58 577 580 O
study 59 64 581 586 O
02 65 67 587 589 O
- 67 68 589 590 O
DK-0022 68 75 590 597 O
and/or 76 82 598 604 O
NIH 83 86 605 608 O
study 87 92 609 614 O
13 93 95 615 617 O
- 95 96 617 618 O
DK-0057 96 103 618 625 O

Psychiatric 0 11 626 637 B-chronic_disease
disorder 12 20 638 646 I-chronic_disease
impeding 21 29 647 655 O
competence 30 40 656 666 O
or 41 43 667 669 O
compliance 44 54 670 680 O

Subjects 0 8 681 689 O
who 9 12 690 693 O
have 13 17 694 698 O
a 18 19 699 700 O
known 20 25 701 706 O
hypersensitivity 26 42 707 723 O
to 43 45 724 726 O
E. 46 48 727 729 B-allergy_name
coli 49 53 730 734 I-allergy_name
derived 54 61 735 742 I-allergy_name
proteins 62 70 743 751 I-allergy_name

TG 0 2 752 754 B-clinical_variable
reduction 3 12 755 764 I-clinical_variable
greater 13 20 765 772 O
than 21 25 773 777 O
or 26 28 778 780 O
equal 29 34 781 786 O
to 35 37 787 789 O
30 38 40 790 792 B-lower_bound
% 40 41 792 793 I-lower_bound

Withdrawal 0 10 794 804 O
of 11 13 805 807 O
metreleptin 14 25 808 819 B-treatment
led 26 29 820 823 O
to 30 32 824 826 O
marked 33 39 827 833 O
worsening 40 49 834 843 O
of 50 52 844 846 O
metabolic 53 62 847 856 O
parameters 63 73 857 867 O

